We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Antibody Cocktail Blocks Growth of Drug-Resistant Lung Tumors in Mouse Model

By LabMedica International staff writers
Posted on 17 Jun 2015
Cancer researchers developed a cocktail of three monoclonal antibodies that was able to halt drug-resistant tumor growth in a mouse xenograft lung cancer model.

Lung cancer patients with primary epidermal growth factor receptor (EGFR) mutations usually respond well to treatment with targeted kinase inhibitors, but almost always develop drug acquire resistance, often due to a second-site mutation (T790M). More...
Clinical trials have tested the ability of a monoclonal antibody (mAb) to EGFR but failed to demonstrate any survival benefits despite the fact that the mAB should have blocked activation of the mutated receptor.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) traced the reason for this failure. By using cell lines with the T790M mutation, they discovered that prolonged exposure to mAbs against only the EGFR triggered molecular network rewiring by (i) stimulating the extracellular signal–regulated kinase (ERK) pathway; (ii) inducing the transcription of HER2 (human epidermal growth factor receptor 2) and HER3, which encode other members of the EGFR family, and the gene encoding HGF (hepatocyte growth factor), which is the ligand for the receptor tyrosine kinase MET, a molecule often expressed in metastatic cancers.

To counter the emergence of this new pathway, the investigators developed mAbs against HER2 and HER3. They reported in the June 2, 2015, online edition of the journal Science Signaling that supplementing the EGFR-specific mAb with those targeting HER2 and HER3 suppressed the compensatory feedback loops that had developed in cultured lung cancer cells. The triple mAb combination targeting all three receptors prevented the activation of ERK, accelerated the degradation of the receptors and inhibited the proliferation of tumor cells but not of normal cells. Furthermore, treatment with the antibody cocktail markedly reduced the growth of tumors in mice xenografted with cells that were resistant to combined treatment with erlotinib and the single function-blocking EGFR mAb.

"Treatment by blocking a single target can cause a feedback loop that ultimately leads to a resurgence of the cancer," said senior author Dr. Yosef Yarden, professor of molecular cell biology at the Weizmann Institute of Science. "If we can predict how the cancer cell will react when we block the growth signals it needs to continue proliferating, we can take preemptive steps to prevent this from happening."

Related Links:

Weizmann Institute of Science



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.